Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2024-12-18 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-12-18 English
Articles of Association
Governance Information Classification · 98% confidence The document is the full text of Pharmaron Beijing Co., Ltd’s Articles of Association, which comprise the company’s internal governance rules, board structure, share issuance and shareholder meeting procedures. This aligns directly with the definition of a Governance Information filing (CGR). It is not an announcement or a summary but the substantive governing document itself.
2024-12-18 English
(I) POLL RESULTS OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2024, THE SECOND A SHARE CLASS MEETING OF 2024 AND THE SECOND H SHARE CLASS MEETING OF 2024 HELD ON DECEMBER 18, 2024&#x3b; AND (II) AME
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement detailing the poll voting results of an extraordinary general meeting (EGM) and related A and H share class meetings, including breakdowns of votes for, against, and abstentions, as well as amendments to the articles of association. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement, which covers official shareholder vote results. Therefore, the appropriate filing type is DVA.
2024-12-18 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return (Form FF305) under Hong Kong Listing Rules, detailing changes in issued shares and treasury shares, including share repurchases (on-market buybacks) and treasury share sales. This type of filing reports the company’s transactions in its own shares. Hence it falls under “Transaction in Own Shares” (POS).
2024-12-18 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a mandatory "Next Day Disclosure Return" (Form FF305) submitted to the Hong Kong Stock Exchange under Main Board Rule 13.25A/GEM Rule 17.27A and Main Board Rule 10.06(4)(a)/GEM Rule 13.13(1). It details share repurchases (treasury share purchases) and on-market sale of treasury shares by Pharmaron Beijing Co., Ltd. This is not a general regulatory announcement, call transcript, earnings release, or issuance of new capital; rather it is a report of the company’s own share transactions (buybacks and treasury sales). According to the classification definitions, this falls squarely under "Transaction in Own Shares (share repurchase/issuance)" (Code: POS).
2024-12-17 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Exchange “Next Day Disclosure Return” (Form FF305) detailing share repurchases (treasury shares) and changes in issued shares per Main Board Rules/GEM Rules. It provides transaction details of the company buying back its own shares as treasury shares. This matches the “Transaction in Own Shares” category (Code: POS).
2024-12-16 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.